Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Novartis CEO Vas Narasimhan. Photo: Ruben Sprich/AFP via Getty Images
Multinational drug conglomerate Novartis won't raise prices on its drugs for the rest of this year, CEO Vas Narasimhan said on an investor call Wednesday.
Why it matters: Novartis' decision comes roughly a week after a Senate report found the company and Michael Cohen, President Trump's former personal attorney, had closer ties than Novartis originally explained. Novartis' pause on drug price hikes also follows Pfizer's decision to delay prices increases on its drugs after Trump sent out critical tweets. But the underlying practices of the drug industry have not changed.